I-MAB (IMAB) Net Margin % : -8,672.21% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. I-MAB's Net Income for the six months ended in Dec. 2023 was $-97.04 Mil. I-MAB's Revenue for the six months ended in Dec. 2023 was $1.12 Mil. Therefore, I-MAB's net margin for the quarter that ended in Dec. 2023 was -8,672.21%.

The historical rank and industry rank for I-MAB's Net Margin % or its related term are showing as below:

IMAB' s Net Margin % Range Over the Past 10 Years
Min: -5304.17 Med: -2580.38 Max: 1131.66
Current: -5304.17

IMAB's Net Margin % is ranked worse than
86.63% of 1032 companies
in the Biotechnology industry
Industry Median: -156.25 vs IMAB: -5304.17

I-MAB Net Margin % Historical Data

The historical data trend for I-MAB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Net Margin % Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-4,840.22

30.53

-2,648.76

1,131.66

-5,301.50

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Margin %	Get a 7-Day Free Trial								-1,786.47	-2,018.58	534.14	-3,931.18	-8,672.21

Competitive Comparison of I-MAB's Net Margin %

For the Biotechnology subindustry, I-MAB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Net Margin % distribution charts can be found below:

* The bar in red indicates where I-MAB's Net Margin % falls into.

I-MAB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

I-MAB's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-205.274	/	3.872
	=	-5,301.50 %

I-MAB's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-97.042	/	1.119
	=	-8,672.21 %

I-MAB (NAS:IMAB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

I-MAB Net Margin % Related Terms

Thank you for viewing the detailed overview of I-MAB's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.